[Alfadil--positive documentation when it comes to safety is missing].
作者信息
Furberg Curt
机构信息
Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, USA.
出版信息
Lakartidningen. 2003 Dec 18;100(51-52):4329; discussion 4330.
PMID:14756103
Abstract
摘要
相似文献
1
[Alfadil--positive documentation when it comes to safety is missing].
Lakartidningen. 2003 Dec 18;100(51-52):4329; discussion 4330.
2
3
[Doxazosin and heart failure: a clinical conclusion is wanted].多沙唑嗪与心力衰竭：需要得出临床结论
Lakartidningen. 2003 Dec 18;100(51-52):4328.
4
[Alfadil and heart failure--clinical conclusions do exist!].
Lakartidningen. 2003 Dec 4;100(49):4112-3.
5
[Misleading advertising claims about the indication of doxazosin (Cardura) for type 2 diabetes mellitus and hypertension].关于多沙唑嗪（可多华）用于2型糖尿病和高血压适应症的误导性广告宣传
Ned Tijdschr Geneeskd. 2003 Jan 18;147(3):135; author reply 135-6.
6
[Doxazosin and heart failure: truthful information--for the sake of patients].
Lakartidningen. 2003 Nov 27;100(48):4011-2.
7
Doxazosin, an inferior antihypertensive agent?
J Hum Hypertens. 2002 Jun;16(6):375-7. doi: 10.1038/sj.jhh.1001313.
8
[Misleading advertising claims about the indication of doxazosin (Cardura) for type 2 diabetes mellitus and hypertension].关于多沙唑嗪（可多华）用于2型糖尿病和高血压适应症的误导性广告宣传
Ned Tijdschr Geneeskd. 2002 Nov 2;146(44):2099-100.
9
Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension.多沙唑嗪：治疗顽固性动脉高血压的安全性与疗效
Blood Press. 2009;18(1-2):74-7. doi: 10.1080/08037050902843726.
10
Doxazosin for the management of hypertension: implications of the findings of the ALLHAT trial.
Am J Hypertens. 2001 Nov;14(11 Pt 1):1170-2. doi: 10.1016/s0895-7061(01)02212-9.
Zotero 插件